Patients' Knowledge and Information Needs about Isotretinoin Therapy Use in Jordan.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
11
2021
revised:
19
01
2022
accepted:
25
01
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Despite being the first-line treatment for severe or moderate acne, isotretinoin has several serious side effects that necessitate the evaluation of patients' knowledge about isotretinoin side effects and its proper use. The current study aim was to explore information needs about isotretinoin by evaluating patients' knowledge about the appropriate use of isotretinoin and its associated side effects. In addition to the sociodemographic variables, a validated online questionnaire was adopted from the literature to evaluate patients' knowledge about isotretinoin use and its potential side effects. Independent The most recognized side effect of isotretinoin therapy was dryness (98.1%). The study patients showed good knowledge about isotretinoin use with a mean knowledge score of 8.1 (SD = 0.7). However, more than half of them (61.0%) mistakenly thought that isotretinoin therapy should be taken continuously for more than 6 months without stop, and some of them did not know that isotretinoin is recommended to be taken with fatty meal (24%) and sunblock (24.6%). Female gender (8.2 (SD = 0.8)) and using isotretinoin for more than 6 months (8.3 (SD = 1.2)) were significantly associated with a higher knowledge score of isotretinoin use ( The lack of patients' information about the potential side effects, duration of therapy, and some instructions on isotretinoin use, such as taking the medication with fatty meal and sunblock, shed the light on the necessity to prepare leaflets, educational brochures, and educational posts via social media in order to improve patients' knowledge about isotretinoin therapy and its optimal use.
Sections du résumé
Background
UNASSIGNED
Despite being the first-line treatment for severe or moderate acne, isotretinoin has several serious side effects that necessitate the evaluation of patients' knowledge about isotretinoin side effects and its proper use.
Objective
UNASSIGNED
The current study aim was to explore information needs about isotretinoin by evaluating patients' knowledge about the appropriate use of isotretinoin and its associated side effects.
Methods
UNASSIGNED
In addition to the sociodemographic variables, a validated online questionnaire was adopted from the literature to evaluate patients' knowledge about isotretinoin use and its potential side effects. Independent
Results
UNASSIGNED
The most recognized side effect of isotretinoin therapy was dryness (98.1%). The study patients showed good knowledge about isotretinoin use with a mean knowledge score of 8.1 (SD = 0.7). However, more than half of them (61.0%) mistakenly thought that isotretinoin therapy should be taken continuously for more than 6 months without stop, and some of them did not know that isotretinoin is recommended to be taken with fatty meal (24%) and sunblock (24.6%). Female gender (8.2 (SD = 0.8)) and using isotretinoin for more than 6 months (8.3 (SD = 1.2)) were significantly associated with a higher knowledge score of isotretinoin use (
Conclusions
UNASSIGNED
The lack of patients' information about the potential side effects, duration of therapy, and some instructions on isotretinoin use, such as taking the medication with fatty meal and sunblock, shed the light on the necessity to prepare leaflets, educational brochures, and educational posts via social media in order to improve patients' knowledge about isotretinoin therapy and its optimal use.
Identifiants
pubmed: 35685597
doi: 10.1155/2022/9443884
pmc: PMC9159128
doi:
Substances chimiques
Dermatologic Agents
0
Isotretinoin
EH28UP18IF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9443884Informations de copyright
Copyright © 2022 Anan S. Jarab et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Dermatol Ther. 2017 Jul;30(4):
pubmed: 28295859
Drugs Real World Outcomes. 2018 Jun;5(2):129-136
pubmed: 29790022
Ther Innov Regul Sci. 2019 Sep;53(5):618-622
pubmed: 30380941
Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):668-673
pubmed: 29726056
Saudi Med J. 2014 Jan;35(1):81-4
pubmed: 24445895
Cureus. 2020 Dec 18;12(12):e12148
pubmed: 33489560
Eur J Dermatol. 2001 Nov-Dec;11(6):538-44
pubmed: 11701404
JAMA. 2001 Apr 25;285(16):2079-81
pubmed: 11311094
Int J Health Sci (Qassim). 2010 Jan;4(1):47-51
pubmed: 21475525
Matern Child Health J. 2006 Sep;10(5 Suppl):S129-35
pubmed: 16850277
Pediatr Dermatol. 2015 Nov-Dec;32(6):e324-5
pubmed: 26584707
CMAJ. 2016 Sep 6;188(12):901
pubmed: 27601629
J Am Acad Dermatol. 2007 Apr;56(4):651-63
pubmed: 17276540
Saudi Pharm J. 2021 Jun;29(6):527-532
pubmed: 34194259
J Dermatol. 1993 Nov;20(11):674-8
pubmed: 8300935
Dermatoendocrinol. 2009 May;1(3):162-9
pubmed: 20436884
Patient Prefer Adherence. 2018 Jan 19;12:153-161
pubmed: 29403267
Dermatol Ther. 2020 Jul;33(4):e13669
pubmed: 32459383
Adolesc Health Med Ther. 2016 Jan 19;7:13-25
pubmed: 26955297
CMAJ. 2013 Mar 19;185(5):411-3
pubmed: 23296582
Eur J Clin Pharmacol. 2006 Aug;62(8):667-74
pubmed: 16791584
Can Fam Physician. 2006 Mar;52:338-9
pubmed: 16926960